Use of the biomarker presepsin for the early and highly specific diagnosis of sepsis
The review of the diagnostic potential of new biomarker of sepsis - presepsin (PSP). The corresponding published data are described and discussed. The main data dealing with PCP are the following:PSP is the principally new biomarker of bacterial and fungi systemic infections;р е к о м е н д а ц и иthe mechanism of PSP production during sepsis induction and development is differing form that of such conventional markers of sepsis as tumor necrosis factor-alpha, interleukin-6, interleukin-10, procalcitonin (PCT) and C-reactive protein the mechanism of PSP production and is associated mainly with activation of phagocytosis;during development of systemic infections, presepsin grows earlier than the other sepsis markers, without regard to their growth or reduction;PSP is diagnosing sepsis before its clinical manifestation with 100 % reliability (confirmed later with hemocultures) and provide the opportunity to initiate a therapy of sepsis before its clinical manifestation and predicts the outcomes.During the monitoring of sepsis PSP (in contrast to other markers) reflects reliably its real dynamics and rapidly changes dependently of an efficiency of therapy and predict relapses of sepsis after its remission when clinical symptoms and values of PCT are normalizing;К л и н и ч е с к и еPSP is not increasing in the absence of infectious complications in surgery, burns and traumas.The results of international and Russian studies demonstrated that PSP is highly efficient marker for early diagnostics and monitoring of systemic infections.